CyteTech is the strategic healthcare investment division of Cells4Life Group LLP, dedicated to translating biological potential into clinical reality.
CyteTech bridges the gap between scientific discovery and patient care. Backed by the infrastructure and sector expertise of the Cells4Life Group, we identify and develop high-impact biotechnologies. We do not merely fund innovation; we provide the operational stability required to bring complex medical advancements to market.
Our investment thesis centres on technologies that address fundamental challenges in modern medicine.
We are dedicated to the advancement of curative treatments. By harnessing the body's own biological mechanisms to repair and regenerate tissue, we aim to deliver solutions that extend healthy life spans and redefine patient care.
The foundation of effective regenerative medicine is cell quality. Our portfolio includes proprietary cell separation technologies deployed across thousands of samples annually, maximising cell recovery and viability to solve critical bottlenecks in the therapeutic supply chain.
We are actively developing next-generation cellular therapies. Our research focuses on translating biological insights into targeted treatments for complex conditions, including aggressive oncological indications.
We welcome enquiries from strategic partners, institutional investors, and innovative biotechnology companies.
[email protected]